Welcome

Welcome to the 2020 AACI/CCAF Annual Meeting!
The two-day, virtual meeting convenes AACI cancer center members with national cancer research and advocacy groups, industry, and government health agencies to develop solutions to common challenges — particularly those that have come to the fore as a result of the COVID-19 pandemic.

Since our 2019 annual meeting, three new cancer center members have joined AACI: Cold Spring Harbor Laboratory Cancer Center, University of Puerto Rico Comprehensive Cancer Center, and Cancer Center at Brown University.

During the meeting AACI will welcome new leadership to its Board of Directors. Dr. Caryn Lerman, director of the USC Norris Comprehensive Cancer Center, has been elected vice president/president-elect. Drs. Cornelia Ulrich and Robert Winn have been elected as new board members, and Dr. Charles S. Fuchs has been appointed to fill the remainder of Dr. Lerman’s term as a regular board member.

AACI extends its appreciation for the service of outgoing board members, Drs. Gerold Bepler and Timothy L. Ratliff, and immediate past president, Dr. Stanton L. Gerson. And please join me in congratulating Dr. Roy A. Jensen on his tenure as AACI president.

Under his leadership, AACI established patient advocacy scholarships for Hill Day, added three new Corporate Roundtable members, introduced a CAR T initiative, and advocated for an increase to the National Cancer Institute R01 payline.

We are pleased to recognize the research achievements of Nobel Laureate Dr. William G. Kaelin, Jr. this year. In addition to receiving AACI’s Distinguished Scientist Award, Dr. Kaelin will present a keynote detailing his long-term research on how cells sense and adapt to changing oxygen levels. We will also honor Nike, Inc., co-founder Phil Knight and his wife, Penny Knight, with the AACI Champion for Cures Award in recognition of their significant financial support of the OHSU Knight Cancer Institute.

This year’s meeting program was jointly formulated by AACI and the Cancer Center Administrators Forum (CCAF). I would like to offer a special thanks to Dr. Steven D. Leach, who chaired the program committee.

The program features panel discussions on topics including cancer care and COVID-19, rightsizing cancer screening, pediatric cancer, palliative and end-of-life care, and basic science. AACI Vice President/President-elect, Dr. Karen E. Knudsen, will introduce her presidential initiative, a podcast series addressing disparities in cancer research and care.

Though I wish we were welcoming you to Kansas City for an in-person meeting, I am thankful for the hard work and expertise of the 2020 AACI/CCAF Annual Meeting Program Committee and AACI staff who helped make this meeting possible.

Sincerely,
Jennifer W. Pegher
Executive Director
Pre-Meeting Sessions

All pre-meeting sessions are virtual. Session times are in Eastern Daylight Time.

Thursday, October 8

11:00 am  Exhibits Opens

12:00 pm  Necessary Innovation: Regulatory Work in the Time Of COVID
Vendor Presentation: Complion

COVID-19 has forced cancer center research staff to rethink how work is done. And it goes without saying, there is no pause for regulatory work as trials continue. The Complion team has made it our goal to do everything we can to make regulatory work not only easier, but possible, during this period of uncertainty. Our software platform allows remote access to regulatory binders: sites can manage their regulatory process virtually and also offer monitors remote access. The result: sites can continue to ensure the highest level of compliance with the least amount of work while maintaining focus on their clinical trials. In this session, Complion shares insight into problems unique to a global pandemic and the solutions to future-proofing regulatory work.

Jaclyn Clark
Complion

12:30 pm  Managing Change in Clinical Trials: Part One
Part one of this two-part Clinical Research Innovation (CRI) session will address how cancer center clinical trials offices (CTO) are adapting to change in the wake of COVID-19, including staffing and operational concerns such as flex schedules, effort tracking, and IT infrastructure. CTO administrative directors, medical directors, managers, and supervisors; deputy/associate directors of clinical research administration; cancer center administrators; research regulatory management and staff; and clinical research finance directors, managers, and supervisors are encouraged to attend.

Moderator: Dr. Theresa L. Werner
Huntsman Cancer Institute, University of Utah

Ms. Tricia Adrales Bentz
Hollings Cancer Center, Medical University of South Carolina

Dr. Bhanu Pappu
UPMC Hillman Cancer Center

Ms. Helen Peck
Wilmot Cancer Institute, UR Medicine

Mr. Michael Sainz
Dartmouth-Hitchcock Norris Cotton Cancer Center

1:20 pm  Managing Change in Clinical Trials: Part Two
Part two of the CRI pre-meeting session will continue the discussion on how cancer center clinical trials offices (CTO) are adapting to change in the wake of COVID-19, including supporting patients in an ever-changing atmosphere, managing trials remotely, the impact on trial enrollments, remote monitoring, and conducting CCSG site visits remotely. CTO administrative directors, medical directors, managers, and supervisors; deputy/associate directors of clinical research administration; cancer center administrators; research regulatory management and staff; and clinical research finance directors, managers, and supervisors are encouraged to attend.

Moderator: Dr. Tara Lin
The University of Kansas Cancer Center

Dr. Stefan C. Grant
Wake Forest Baptist Comprehensive Cancer Center

Ms. Collette Houston
Memorial Sloan Kettering Cancer Center

Ms. Melissa Nashawati
Mays Cancer Center, UT Health San Antonio

Mr. Alex Zafirovski
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

2:00 pm  AACI Government Relations (GR) Forum Meeting
Session not CME accredited
The GR forum meeting provides an opportunity for government relations professionals from AACI member cancer centers to discuss federal and state policy issues that impact the cancer community. The meeting will feature discussions covering a variety of topics, including presentations from 2020 presidential campaign surrogates.

Moderator: Mr. John DeMuro
Moffitt Cancer Center

Moderator: Mr. Peter J. Mackler
City of Hope Comprehensive Cancer Center

U.S. Representatives Ami Bera (D-CA) and Raul Ruiz (D-CA)
Biden Campaign

Mr. Jason Miller
Senior Advisor, Trump Campaign
**Agenda**

*Virtual meeting. All session times are in Eastern Daylight Time.*

**Monday, October 12**

**8:00 am** Exhibits Open

**8:30 am** Welcome and Business Meeting

- Dr. Roy A. Jensen  
The University of Kansas Cancer Center

- Ms. Jennifer W. Pegher  
Association of American Cancer Institutes

- Mr. Jeff Walker  
City of Hope National Medical Center

- Dr. Kimberly F. Kerstann  
Winship Cancer Institute of Emory University

- Dr. Steven D. Leach  
Dartmouth College  
Dartmouth-Hitchcock Norris Cotton Cancer Center

**9:15 am** 2020 AACI Distinguished Scientist Award – Opening Keynote

**Introduction and Presentation of Award**

- Dr. Laurie H. Glimcher  
Dana-Farber Cancer Institute  
Harvard Medical School

- Dr. William G. Kaelin, Jr.  
Howard Hughes Medical Institute  
Dana-Farber Cancer Institute  
Harvard Medical School

**10:30 am** Maintaining Cancer Center Excellence and Momentum in the Age of COVID

With the myriad unknowns and upheavals generated by the coronavirus pandemic, cancer centers are looking for—and finding—ways to secure institutional commitment, prioritize cancer centers’ missions, unlock new resources, and preserve staffing levels. A panel of cancer center leaders will talk about steps they’ve taken in response to COVID-19, including re-examining the National Cancer Institute’s Cancer Center Support Grant requirements with an eye toward creating more robust online platforms for education and community outreach, rebuilding clinical trials, and rewarding creativity and innovation.

**Moderator: Dr. Steven K. Libutti**  
Rutgers Cancer Institute of New Jersey

- Dr. Erin Kobetz  
Sylvester Comprehensive Cancer Center  
University of Miami Health System

- Dr. Stephen D. Nimer  
Sylvester Comprehensive Cancer Center  
University of Miami Health System

- Dr. Anil K. Rustgi  
Herbert Irving Comprehensive Cancer Center  
Columbia University Irving Medical Center

**11:30 am** Rightsizing Cancer Screening: Clarifying Conflicting Recommendations

With often conflicting data and recommendations, navigating cancer screening can be a tricky business. Now, with COVID-19 making visits to clinics problematic at best, even clear screening guidelines have become difficult to follow. Beyond the range of cancer types, screening complexity is compounded when attempting to focus the lens on any one group. Gender identity, socioeconomic status, age, place of residence, and other factors often require flexibility in determining how, where, and when to provide cancer screening. Panelists will discuss the need for shared decision-making when defining and adopting screening guidelines, how to ensure inclusion, and how to get the right screening for the right person.

**Moderator: Dr. Harry de Koning**  
Erasmus MC  
University Medical Center Rotterdam

- Dr. Ronald Chen  
The University of Kansas Cancer Center

- Dr. Ruth B. Etzioni  
Fred Hutchinson Cancer Research Center
12:30 – 12:45 pm Break

12:45 pm Champion for Cures Award

Introduction and Presentation of Award

Dr. Brian Druker
OHSU Knight Cancer Institute

Phil and Penny Knight

1:00 pm Lessons From Pediatric Cancer: Genomics, Targeted Therapies, and Survivorship

NCI Cancer Center Support Grant (CCSG) guidelines require that centers make specific efforts to address childhood cancer — the leading cause of death by disease among children over one year of age in the developed world. The field of pediatric cancer is drawing renewed interest, with recent research showing that 55 percent of the gene mutations recurrently found in pediatric cancers are not found in adult cancers. Consequently, the old “trickle-down” model of therapy from adult to pediatric cancers will fail to address the majority of drivers in childhood cancers. Recent insights into pediatric cancer and survivorship will be the focus of this session.

Moderator: Dr. Charles W.M. Roberts
Comprehensive Cancer Center
St. Jude Children’s Research Hospital

Dr. Smita Bhatia
O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham

Dr. Kimberly Stegmaier
Dana-Farber Cancer Institute
Harvard Medical School

Dr. Jinghui Zhang
Comprehensive Cancer Center
St. Jude Children’s Research Hospital

2:00 pm CCSG: Charting New Territory

The COVID-19 pandemic has underscored the need for flexibility in cancer center operations. This session will focus on select cancer centers that have recently completed the National Cancer Institute’s Cancer Center Support Grant (CCSG) site visits in a virtual format. Panelists will share best practices for satisfying CCSG requirements while learning to navigate the “new normal.”

Moderator: Ms. Julie Brabbs
University of Michigan Rogel Cancer Center

Mr. David Darr
UNC Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill

Mr. David Gosky
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Mr. John Pounardjian
Case Comprehensive Cancer Center

Dr. Robert H. Vonderheide
Abramson Cancer Center of the University of Pennsylvania

Mr. Alex Zafirovski
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

3:00 pm CCAF Business Meeting
(Closed session for members of CCAF)

3:00 pm 8th Annual AACI PCLI Meeting: Hastening Progress Towards Cancer Care Equity

Panelists will discuss how disparities are defined, where disparities exist in cancer health today, and how diversity, equity, and inclusion will define the future of cancer care.

Dr. Claire F. Verschraegen
The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute

Dr. Edith Mitchell
Sidney Kimmel Cancer Center at Jefferson Health

Dr. Otis W. Brawley
Sidney Kimmel Comprehensive Cancer Center at John Hopkins University

Dr. Carmen E. Guerra
Abramson Cancer Center of the University of Pennsylvania

Dr. Melissa A. Simon
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
**Agenda**

**4:30 pm** **Delivering Precision Oncology: Partnerships and Opportunities**

Vendor Presentation: Caris Life Sciences

In this session, Dr. Chadi Nabhan will describe the attributes that position a precision oncology program as best in practice. He will outline how Caris collaborates with institutions with existing precision oncology programs as well as with institutions that are working on developing a clinical precision oncology platform. Dr. Nabhan will also share some case studies that outline how these programs provide research, mentorship, and leadership opportunities.

Chadi Nabhan, MD, MBA, FACP
Precision Oncology Alliance
University of South Carolina
Department of Clinical Pharmacy & Outcomes Sciences

**5:00 pm** **Closing Remarks**

Dr. Steven D. Leach
Dartmouth College
Dartmouth-Hitchcock Norris Cotton Cancer Center

---

**Tuesday, October 13**

**8:00 am** **Exhibits Open**

**8:30 am** **New Presidential Initiative: Mitigating Cancer Disparities**

Dr. Karen E. Knudsen has selected cancer disparities as the focus of her presidential initiative. To raise awareness and learn what cancer centers are doing to mitigate disparities, Dr. Knudsen and AACI will launch a podcast series featuring conversations with cancer center leaders. Her presentation will also examine results from a recent cancer center leadership diversity survey administered by AACI and The Cancer Letter.

Dr. Karen E. Knudsen
Sidney Kimmel Cancer Center at Jefferson Health

**9:00 am** **How Cancer Centers Are Addressing Health Disparities and Social Injustice**

Recognizing that the burden of cancer falls disproportionately on communities of color—particularly Black communities—AACI is committed to promoting health equity. Recent research has shown that underrepresented minority scientists are more likely to conduct health disparities research. Yet despite the growing interest in diversity, there is only one African-American director among NCI’s 71 designated cancer centers. Panelists will discuss how to diversify cancer centers from the top down, including mapping out processes that each cancer center can implement to achieve that goal.

Moderator: Dr. Robert A. Winn
VCU Massey Cancer Center

Dr. Christopher Li
Fred Hutchinson Cancer Research Center

Dr. Ana María López
Sidney Kimmel Cancer Center at Jefferson

Dr. Jamie Mitchell
University of Michigan

**10:00 am** **NCI Director’s Report**

An expanding roster of approved cancer drugs and devices, declining mortality, and a spike in grant applications to the NCI point to a remarkable era in cancer research. Dr. Norman E. Sharpless will highlight the NCI’s dedication to investing in research infrastructure at the institutions where investigators make their key discoveries, as well as its careful planning for budget uncertainty to balance the increasing demand for new grants with previous commitments.

Dr. Norman E. Sharpless
National Cancer Institute

**11:00 – 11:15 am** **Break**
11:15 am  Care Across the Continuum: Cancer Center Approaches to Palliative and End-of-Life Care

Treatment advances are significantly extending the lives of more cancer patients, and palliative and end-of-life care is attracting more attention and resources at cancer centers. New technologies and differences in cultural and generational attitudes toward serious illness can also complicate the management of late-stage cancer care. Panelists will share their latest thinking and best practices in areas such as pediatric cancer survivorship, narrative medicine, and music therapy.

Moderator: Dr. Kathryn B. Kirkland
Dartmouth-Hitchcock Norris Cotton Cancer Center

Dr. Rachelle Bernacki
Dana-Farber Cancer Institute
Harvard Medical School

Ms. Rachel Cannady
American Cancer Society

Dr. John Sweetenham
Simmons Comprehensive Cancer Center
UT Southwestern Medical Center

12:15 pm  Overview of the Basic Science Centers

AACI’s basic science center members focus on laboratory research and collaborate with other institutions to apply their findings to deliver better treatments. In this session, directors from four basic science centers will talk about work at their centers, including: RNA as a drug target in cancer; using basic models and technology development; new therapeutic approaches in pancreatic cancer; and how a basic science center can contribute to precision medicine beyond checkpoint inhibitors and CAR T technology.

Moderator: Dr. Timothy L. Ratliff
Purdue University Center for Cancer Research

Dr. Dario C. Altieri
The Wistar Institute

Dr. Rueben J. Shaw
Salk Institute Cancer Center

Dr. David Spector
Cold Spring Harbor Laboratory Cancer Center

Dr. David Tuveson
Cold Spring Harbor Laboratory Cancer Center

1:15 – 1:30 pm  Break

1:30 pm  Update on the NCI Cancer Centers Program

Dr. Henry Ciolino will lead a discussion about the NCI’s goals for the national cancer research enterprise; standards for developing new and better approaches to preventing, diagnosing, and treating cancer; and the optimal distribution of limited federal cancer research funds at AACI cancer centers.

Dr. Henry Ciolino
National Cancer Institute

2:30 pm  A Changing Landscape: Technology, Access, and Policy in Rural Oncology

Developing sustainable oncology programs has historically been a major challenge for rural hospitals. Beyond traditional barriers like transportation, delivering cancer care outside urban areas is complicated as many rural communities become older and more diverse and experience gaps in access to technology. Panelists will focus on specific issues around “rurality”—defining what impacts rural cancer care delivery—the implementation of telehealth and other technologies, access to clinical trials, and public policy initiatives.

Moderator: Dr. Steven D. Leach
Dartmouth College
Dartmouth-Hitchcock Norris Cotton Cancer Center

Dr. Michael Businelle
Stephenson Cancer Center, University of Oklahoma

Dr. Tracy Onega
Huntsman Cancer Institute, University of Utah

Dr. Laura Tenner
Mays Cancer Center, UT Health San Antonio
**Agenda**

**3:30 pm** Leveraging Integrated Clinical Research Solutions to Streamline Your Trials  
Vendor Presentation: Advarra

In this presentation, Advarra will discuss the role of integrated solutions in helping centers build more efficient, effective workflows. They will also highlight how integrations can help streamline document management, enable remote workflows, reduce IRB turnaround time, and more, improving compliance while reducing study startup timelines.

*Cheryl Byers*  
Advarra

*Carrie Nemke*  
Advarra

**4:00 pm** Closing Remarks

*Dr. Roy A. Jensen*  
The University of Kansas Cancer Center

*Dr. Karen E. Knudsen*  
Sidney Kimmel Cancer Center at Jefferson Health

**Continuing Medical Education**

**Joint Providership Statement**  
Jointly provided by the American Association for Cancer Research (AACR) and the Association of American Cancer Institutes (AACI).

**Accreditation**  
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the AACR and AACI. The AACR is accredited by the ACCME to provide continuing medical education (CME) for physicians.

**Credit Designation**  
The AACR has designated this internet live activity for a maximum of 14.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

**Claiming CME Credit**  
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)™ for this live continuing medical education activity must complete the online CME Request for Credit Survey by **Tuesday, November 24, 2020**. Certificates will only be issued to those who complete the survey. The Request for Credit Survey will be available via a link on the conference website and via email. Your CME certificate will be sent to you via email after the completion of the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 14.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

To receive ABIM MOC, participants must request MOC in the CME Request for Credit Survey and complete all questions. Once these steps are completed, AACR will submit your completion information via the ACCME’s Program and Activity Reporting System for the purpose of granting MOC points.
Continuing Medical Education

Statement of Educational Need, Target Audience, and Learning Objectives
Despite enormous progress in the field, cancer continues to be a global public health challenge, accounting for one in every six deaths that occur around the world. In the United States alone, it is predicted that more than 600,000 people will die from some form of cancer in 2020, making it the second most common cause of death after heart disease.

With the quickening pace of discoveries in basic, translational, and clinical research, the battle against cancer is rapidly moving forward. This is due in large part to the advent of new technologies, such as liquid biopsies, and our growing knowledge about how to activate the immune system to develop new immunotherapies. However, understanding and combating cancer requires leadership armed with up-to-date information about advanced technology and proven methods for its implementation.

The AACI/CCAF annual meeting convenes cancer center directors and executive-level administrators with leaders of national cancer research and advocacy groups, industry, and government health agencies to develop solutions to common challenges at cancer centers and to share best practices. Given the complexity of cancer screening—from conflicting recommendations to varied patient populations—flexibility and shared-decision making are required when determining how, where, and when to provide cancer screening.

Researchers, physicians, and other health care professionals who attend the meeting should be able to summarize the program content, discuss its application in clinical practice, and convey the information to faculty and staff at their cancer centers.

After participating in this CME activity, physicians should be able to describe and discuss:

1. Factors in cancer screening complexity and the importance of shared decision-making when defining and adopting screening guidelines, how to ensure inclusion, and how to get the right screening for the right person
2. The impact of new technologies and differences in cultural and generational attitudes on palliative and end-of-life care and best practices in areas such as pediatric cancer survivorship, narrative medicine, and music therapy
3. How cancer centers are working to maintain excellence and prioritize their missions while confronting the coronavirus pandemic, including enhancing online community outreach and re-examining clinical trial management
4. New methods that cancer centers are employing to roll back inequality in their waiting rooms, laboratories, and office suites, as well as in the communities outside their front doors
5. Survivorship for young patients and the growing interest in pediatric cancer care and research at cancer centers

Continuing Medical Education

6. Compliance with current National Cancer Institute (NCI) Cancer Center Support Grant (CCSG) guidelines
7. Ensuring quality cancer care, including enrolling patients in clinical trials, in rural communities
8. Research at basic science cancer centers, including RNA as a drug target in cancer; using basic models and technology development; new therapeutic approaches in pancreatic cancer; and basic science contributions to precision medicine
9. The NCI’s priorities, policies, strategies, and goals for the national cancer research enterprise, and their relationship to academic cancer centers

Americans with Disabilities Act
It is the policy of AACR and AACI not to discriminate against any person on the basis of disabilities. If you feel you need services or auxiliary aids mentioned in this act to fully participate in this CME activity, please contact 412-647-6111 or attach a note to your registration form.

Disclosure Statement
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference and on the website.

Target Audience
This transdisciplinary conference is designed for basic and clinical scientists, as well as for physician-scientists from academia, industry, government, and other institutions with interest in innovative systems and technologies for diagnosing, preventing, and treating cancer and its long-term effects. All attendees have a significant impact on cancer research and patient care.

Attendees may include:

• Leaders of AACI’s academic and freestanding cancer research centers, including cancer center directors, executive administrators, and other top scientific and clinical staff
• Leaders from industry and government agencies as well as those of cancer research and advocacy organizations
• Medical professionals, including oncologists, pharmacists, radiologists, nuclear medicine physicians, nurses, and psychologists
• Social workers, cancer communication specialists, public health leaders, and faculty members who focus on cancer

Questions about CME?
Please contact the Office of CME at 215-440-9300 or cme@aacr.org.
Awardee Profiles

2020 AACI Distinguished Scientist Award

William G. Kaelin, Jr., MD
Dana-Farber Cancer Institute, Harvard Medical School

Dr. William G. Kaelin, is the Sidney Farber Professor of Medicine in the Department of Medicine at Dana-Farber Cancer Institute and the Brigham and Women’s Hospital, Harvard Medical School; and Howard Hughes Medical Institute investigator. AACI is recognizing Dr. Kaelin with the Distinguished Scientist Award for his long-term research on how cells sense and adapt to changing oxygen levels.

The 2019 Nobel Prize in Physiology or Medicine was awarded jointly to Dr. Kaelin, Sir Peter J. Ratcliffe, and Gregg L. Semenza. Dr. Kaelin and his collaborators delineated the molecular events used by almost all multi-cellular animals to attune themselves to varying quantities of oxygen. These findings are leading to new therapeutics for disorders ranging from cancer to cardiovascular disease. For example, they provided the rationale for the development of drugs that inhibit the HIF transcription factor, or HIF-responsive growth factors such as VEGF, for kidney cancer.

Recent AACI Distinguished Scientist honorees include Drs. Douglas R. Lowy, Charles Perou, Carl June, James Allison, and Lewis Cantley.

2020 AACI Champion for Cures Award

Phil and Penny Knight

Nike, Inc. co-founder Phil Knight and his wife, Penny, will receive the 2020 AACI Champion for Cures Award, in recognition of their transformational philanthropy that advances our shared vision of a future without cancer.

The Knights have demonstrated their commitment to the cancer community for over a decade, beginning with a $100 million gift in 2008 that was used to recruit the best and brightest researchers to the Oregon Health and Science University (OHSU). Beyond their significant financial support, the Knights have also helped build a network of people who are emotionally—and financially—invested in the success of Knight Cancer Institute.

In 2015, the OHSU Knight Cancer Institute announced that it had achieved a $500 million fundraising challenge set by the Knights, raising $1 billion for cancer research. The Knight Cancer Challenge garnered support from donors in every state in the nation and 14 countries. Donors were inspired by plans for the first grand-scale program of its kind dedicated to radically transforming early detection of lethal cancers.

The Champion for Cures Award was established as an annual award in 2018 to recognize philanthropic support of AACI cancer centers.
Exhibitors

The American Association for Cancer Research (AACR) and the Association of American Cancer Institutes (AACI) express appreciation to the following companies for their support of this educational activity by providing exhibit fees:

Advarra
Advarra empowers institutions to manage studies more easily, improve compliance, and streamline operations as the premier provider of global research compliance services, offering IRB, IBC, consulting, and research technology. Advarra technology solutions (formerly Forte) provide clinical trial management, clinical data management, and research administration for more than 75 percent of NCI-Designated Cancer Centers.

With a strong belief in community, collaboration, and standards-based development, the company also facilitates the Onsemble Community, a customer-exclusive group for peer networking, best practices, and support. Additionally, Advarra helps make research altogether better with proven capabilities in research administration, HRPP, biosafety, billing compliance, regulatory, GxP auditing, clinical quality assurance, and interim professional staffing. For more information, visit advarra.com.

Caris Life Sciences®
Caris Life Sciences® is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation. The company's suite of market-leading molecular profiling offerings assess DNA, RNA, and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Asia, and other international markets. To learn more, please visit CarisLifeSciences.com or follow us on Twitter (@CarisLS).

Complion
Complion is the pioneer of eRegulatory, created by a researcher for researchers. The Complion regulatory document and workflow management platform improves efficiency, compliance and transparency for research sites and sponsors. It stores, organizes and routes all regulatory documentation involved in a clinical trial allowing for seamless, paperless processes. Going beyond simply digitizing documentation, Complion leverages advanced technology to intelligently file documents and provide controlled access to staff and monitors. The result: better organization and instant process insight. Complion provides unsurpassed monitoring benefits, garnering overwhelming industry support, and has been accessed by more Sponsors and CROs than other eRegulatory platforms.

Deep 6 AI®
Deep 6 AI® uses artificial intelligence and natural language processing on medical records so you can find and validate the patients you need to run a successful trial — in a matter of minutes. Designed to put recruitment power into the hands of researchers, Deep 6 transforms trial criteria into an AI-powered search query. The tool then lets research staff search both structured and unstructured medical data — like physicians’ notes and pathology reports — so they can find and screen more, better-matching patients for their most complex trials more quickly. The Deep 6 platform is EMR-agnostic and allows users to identify, screen, and recruit patients in a HIPAA- and IRB-compliant manner. Deep 6 AI was founded in 2015 and is based in Pasadena, CA. Come visit our virtual table or find out more at deep6.ai.

Huron Consulting Group
Huron’s Cancer Center Practice is composed of leaders with 20-plus years of front-line experience in cancer centers. Huron’s deep understanding of the national NCI landscape and firsthand knowledge of best practices will facilitate improvement of your center’s performance across multiple dimensions by tailoring approaches and solutions to your center’s goals, issues, and organizational environment. Huron has partnered with institutions across the country in supporting the development of a vibrant research enterprise, enhancing clinical research operations, streamlining research administration, providing strategic planning guidance, and preparing for National Cancer Institute designation.

nCoup
nCoup provides innovative cloud solutions that address operational needs of organizations conducting clinical research. nCoup recently launched nCartes, the next generation EHR to EDC clinical data transport platform that enables sites and sponsors to harness electronic medical records to populate EDC systems and fulfill clinical trials. nCartes has been proven to reduce the time and cost of data entry on some cancer clinical trials by 50 percent. nCoup leverages nCoup’s extensive and deep EHR integration and clinical trials software expertise to deliver nCartes. nCoup, Inc. is privately held with headquarters in Fremont, California. For more information on nCoup, please visit ncoup.com. For more information on nCartes, please visit ncartes.ncoup.com.
Exhibitors

The Society for Immunotherapy of Cancer (SITC)
The Society for Immunotherapy of Cancer (SITC) is a 501(c)(3) not-for-profit medical professional society of influential research scientists, physician scientists, clinicians, patients, patient advocates, government representatives, and industry leaders dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Currently, SITC has more than 3,000 members who represent over 35 medical specialties in 48 countries.

Veeva
Veeva offers a suite of applications built specifically for research sites and institutions with connectivity to sponsors and patients to reduce complexity and advance research. With Veeva, you can focus less on technology and more on your research. Veeva Systems Inc. is the leader in cloud-based software for the global clinical research industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 875 customers, ranging from the world’s largest pharmaceutical companies to emerging investigative sites.

Support

Acknowledgment of Commercial Support
The American Association for Cancer Research (AACR) and the Association of American Cancer Institutes (AACI) express appreciation to the following companies for their support of this educational activity by providing an unrestricted educational grant:
- Astra Zeneca
- Novartis
- Pfizer
- Varian Medical Systems

Acknowledgment of Programmatic Support
AACI gratefully acknowledges the following organizations for providing program and exhibit support:
- Advarra
- Caris Life Sciences®
- Complion
- Deep 6 AI®
- Essex
- Florence
- Huron Consulting Group
- nCoup
- The Society for Immunotherapy of Cancer (SITC)
- Veeva

Support as of September 30, 2020
Disclosure of Financial Relationships

In compliance with the standards set by the Accreditation Council for Continuing Medical Education (ACMCE), it is the policy of the American Association for Cancer Research (AACR) that the information presented at ACMCE activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this ACMCE activity.

Relationships are abbreviated as follows: E, Employee of listed company; G, Grant/research support recipient; A, Advisor or review panel member; C, Consultant; S, Stock shareholder; SB, Speakers’ bureau; H, Honoraria; O, Other.

<table>
<thead>
<tr>
<th>First Name</th>
<th>Last Name</th>
<th>Company</th>
<th>Relationships</th>
<th>Type</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mindy</td>
<td>Roberts</td>
<td>OHSU Knight Cancer Institute</td>
<td>No Relationships</td>
<td>Program Committee</td>
<td>Speaker</td>
</tr>
<tr>
<td>Albert</td>
<td>Allen</td>
<td>The Victor Institute</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Thaddeus</td>
<td>Antkiewicz</td>
<td>Association of American Cancer Institutes</td>
<td>No Relationships</td>
<td>Program Committee</td>
<td>Speaker</td>
</tr>
<tr>
<td>Tessa</td>
<td>Arakawa</td>
<td>Hollings Cancer Center, Medical University of South Carolina</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Rachel</td>
<td>Barsky</td>
<td>Dana-Farber Cancer Institute, Harvard Medical School</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Smita</td>
<td>Bhushan</td>
<td>O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Jule</td>
<td>Brubacher</td>
<td>University of Michigan Roger Cancer Center</td>
<td>No Relationships</td>
<td>Program Committee</td>
<td>Speaker</td>
</tr>
<tr>
<td>Ooi</td>
<td>Bravely</td>
<td>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Michael</td>
<td>Bussell</td>
<td>Stephenson Cancer Center, University of Oklahoma</td>
<td>E,G,H,D</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Rachel</td>
<td>Canary</td>
<td>American Society</td>
<td>No Relationships</td>
<td>Program Committee</td>
<td>Speaker</td>
</tr>
<tr>
<td>Ronald</td>
<td>Chen</td>
<td>The University of Kansas Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Henry</td>
<td>Collier</td>
<td>National Cancer Institute</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>David</td>
<td>Derer</td>
<td>UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Harry</td>
<td>de Koning</td>
<td>Erasmus MC, University Medical Center Rotterdam</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Ruffi</td>
<td>Edlböck</td>
<td>Fred Hutchinson Cancer Research Center</td>
<td>UOKE, SRSN Medical</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>David</td>
<td>Givens</td>
<td>The Ohio State University Comprehensive Cancer Care-The James</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Stefan</td>
<td>Grant</td>
<td>Wake Forest Baptist Comprehensive Cancer Center</td>
<td>Theralinc Inc</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Carmen</td>
<td>Guzmán</td>
<td>Abramson Cancer Center of the University of Pennsylvania</td>
<td>Fresenius, Guardant, BMS</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Jaime</td>
<td>Hoffer</td>
<td>Association of American Cancer Institute</td>
<td>No Relationships</td>
<td>Program Committee</td>
<td>Speaker</td>
</tr>
<tr>
<td>Collette</td>
<td>Houston</td>
<td>Memorial Sloan-Kettering Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Roy</td>
<td>Jansen</td>
<td>The University of Kansas Cancer Center</td>
<td>No Relationships</td>
<td>Program Committee</td>
<td>Speaker</td>
</tr>
<tr>
<td>William</td>
<td>Keeling</td>
<td>Howard Hughes Medical Institute, Dana-Farber Cancer Institute, Harvard Medical School</td>
<td>Howard Hughes Medical Institute, HHMI, NCI, BCRF, Lilly Pharmaceuticals</td>
<td>E,G,A,S,</td>
<td>Speaker</td>
</tr>
<tr>
<td>Kimberly</td>
<td>Keestam</td>
<td>Winship Cancer Center of Emory University</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Kathryn</td>
<td>Kimbrell</td>
<td>Dartmouth-Hitchcock Norris Cotton Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Karen</td>
<td>Knudsen</td>
<td>Sidney Kimmel Cancer Center at Jefferson Health</td>
<td>No Relationships</td>
<td>Program Committee</td>
<td>Speaker</td>
</tr>
<tr>
<td>Erin</td>
<td>Kabiron</td>
<td>Sylvester Comprehensive Cancer Center, University of Miami Health System</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Steven</td>
<td>Laach</td>
<td>Dartmouth College, Dartmouth-Hitchcock Norris Cotton Cancer Center</td>
<td>Epigenomics Pharmacology, NYRO Therapeutics,</td>
<td>A</td>
<td>Speaker</td>
</tr>
<tr>
<td>Christopher</td>
<td>Li</td>
<td>Fred Hutchinson Cancer Research Center</td>
<td>No Relationships</td>
<td>Program Committee</td>
<td>Speaker</td>
</tr>
<tr>
<td>Steven</td>
<td>Libutti</td>
<td>Rutgers Cancer Institute of New Jersey</td>
<td>No Relationships</td>
<td>Program Committee</td>
<td>Speaker</td>
</tr>
<tr>
<td>Kari</td>
<td>Lim</td>
<td>The University of Kansas Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Ana Maria</td>
<td>Lopez</td>
<td>Sidney Kimmel Cancer Center at Jefferson Health</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Edith</td>
<td>Mitchell</td>
<td>Sidney Kimmel Cancer Center at Jefferson Health</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Melissa</td>
<td>Mattison</td>
<td>Mab Science Inc, UT Health San Antonio</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Stephen</td>
<td>Nimer</td>
<td>Sylvester Comprehensive Cancer Center, University of Miami Health System</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Tracy</td>
<td>Onega</td>
<td>Huntsman Cancer Institute, University of Utah</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Bharti</td>
<td>Papadakis</td>
<td>UPMC Hillman Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Helen</td>
<td>Pack</td>
<td>Winship Cancer Institute, Emory University</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Jennifer</td>
<td>Pegger</td>
<td>Association of American Cancer Institute</td>
<td>No Relationships</td>
<td>Program Committee</td>
<td>Speaker</td>
</tr>
<tr>
<td>John</td>
<td>Pounardjian</td>
<td>Case Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Timothy</td>
<td>Ralph</td>
<td>Purdue University Center for Cancer Research</td>
<td>No Relationships</td>
<td>Program Committee</td>
<td>Speaker</td>
</tr>
<tr>
<td>Charles</td>
<td>Roberts</td>
<td>Comprehensive Cancer Center, St. Jude Children’s Research Hospital</td>
<td>Epix Therapeutics</td>
<td>C</td>
<td>Program Committee</td>
</tr>
<tr>
<td>Mindy</td>
<td>Roberts</td>
<td>OHIO Knight Cancer Institute</td>
<td>No Relationships</td>
<td>Program Committee</td>
<td>Speaker</td>
</tr>
<tr>
<td>AHI</td>
<td>Rustgi</td>
<td>Hebrew Israeli Cancer Center, Columbia University Irving Medical Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Michael</td>
<td>Saracino</td>
<td>Memorial Sloan-Kettering Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Norman</td>
<td>Sharpless</td>
<td>National Cancer Institute</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Reuben</td>
<td>Shaw</td>
<td>Salk Institute Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Melissa</td>
<td>Shettar</td>
<td>Robert H. Lurie Comprehensive Cancer Center of Northwestern University</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Matthew</td>
<td>Stiller</td>
<td>Cold Spring Harbor Laboratory Cancer Center</td>
<td>Johns Hopkins Kimmel Cancer Center</td>
<td>G,C,S</td>
<td>Speaker</td>
</tr>
<tr>
<td>Kimberly</td>
<td>Stoecker</td>
<td>Dana-Farber Cancer Institute, Harvard Medical School</td>
<td>Novartis, Aaron Therapeutics, Krios Bio</td>
<td>G,C,A</td>
<td>Speaker</td>
</tr>
<tr>
<td>John</td>
<td>Sweetman</td>
<td>Simon Comprehensive Cancer Center, UT Southwestern Medical Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Laura</td>
<td>Winer</td>
<td>Mayo Clinic Cancer Center, UF Health San Antonio</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>David</td>
<td>Tuveson</td>
<td>Cold Spring Harbor Laboratory Cancer Center</td>
<td>Leap Therapeutics, Soseki Oncology, Blyth Therapeutics, MSIBU Therapeutics, Nitrogen, ONKO</td>
<td>A,C,G,D</td>
<td>Speaker</td>
</tr>
<tr>
<td>Claire</td>
<td>Verschraegen</td>
<td>The Ohio State University Comprehensive Cancer Center-The James</td>
<td>CellTron</td>
<td>A</td>
<td>Speaker</td>
</tr>
<tr>
<td>Robert</td>
<td>Vonderheide</td>
<td>Abramson Cancer Center of the University of Pennsylvania</td>
<td>CellBx, Lilly, MedImmune, Varalax, Apeagen</td>
<td>C,G</td>
<td>Speaker</td>
</tr>
<tr>
<td>Pat</td>
<td>Walker</td>
<td>City of Hope National Medical Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Thaisa</td>
<td>Wiemer</td>
<td>Huntsman Cancer Institute, University of Utah</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Robert</td>
<td>Winn</td>
<td>VCU Massey Cancer Center</td>
<td>No Relationships</td>
<td>Program Committee</td>
<td>Speaker</td>
</tr>
<tr>
<td>Aleksandar</td>
<td>Zafirovska</td>
<td>Robert H. Lurie Comprehensive Cancer Center of Northwestern University</td>
<td>No Relationships</td>
<td>Program Committee</td>
<td>Speaker</td>
</tr>
<tr>
<td>Jinghui</td>
<td>Zhang</td>
<td>Comprehensive Cancer Center, St. Jude Children’s Research Hospital</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
</tbody>
</table>
### CME-Approved Sessions Worksheet

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Title</th>
<th>Approved Credits</th>
<th>Claimed Credits</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Thursday</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10/08/20</td>
<td>12:30-1:15 pm</td>
<td>Managing Change in Clinical Trials - Part 1</td>
<td>.75</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1:15-2:00 pm</td>
<td>Managing Change in Clinical Trials - Part 2</td>
<td>.75</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Maximum Approved Credits for 10/08/20</strong></td>
<td>1.5</td>
<td>TOTAL:</td>
<td></td>
</tr>
<tr>
<td><strong>Monday</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10/12/20</td>
<td>9:15-10:15 am</td>
<td>2020 AACI Distinguished Scientist Award</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10:30-11:30 am</td>
<td>Maintaining Cancer Center Excellence and Momentum in the Age of COVID</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>11:30-12:30 pm</td>
<td>Rightsizing Cancer Screening: Clarifying Conflicting Recommendations</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1:00-2:00 pm</td>
<td>Lessons From Pediatric Cancer: Genomics, Targeted Therapies, and Survivorship</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2:00-3:00 pm</td>
<td>CCSG: Charting New Territory</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3:00-4:30 pm</td>
<td>AACI PCLI: Hastening Progress Towards Cancer Care Equity</td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Maximum Approved Credits for 10/12/20</strong></td>
<td>6.5</td>
<td>TOTAL:</td>
<td></td>
</tr>
<tr>
<td><strong>Tuesday</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10/13/20</td>
<td>8:30-9:00 am</td>
<td>New Presidential Initiative: Mitigating Cancer Disparities</td>
<td>0.5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>9:00-10:00 am</td>
<td>How Cancer Centers are Addressing Health Disparities and Social Injustice</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10:00-11:00 am</td>
<td>NCI Director’s Report</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>11:15-12:15 pm</td>
<td>Care Across the Continuum: Cancer Center Approaches to Palliative and End-of-Life Care</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>12:15-1:15 pm</td>
<td>Basic Science Centers</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1:30-2:30 pm</td>
<td>Update on the NCI Cancer Centers Program</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2:30-3:30 pm</td>
<td>A Changing Landscape: Technology, Access, and Policy in Rural Oncology</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Maximum Approved Credits for 10/13/20</strong></td>
<td>6.5</td>
<td>TOTAL:</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Maximum CME Credits Approved</strong></td>
<td>14.5</td>
<td>TOTAL:</td>
<td></td>
</tr>
</tbody>
</table>

---

**Integrated research compliance and technology solutions to streamline your trials**

Advarra empowers you to manage studies more easily, improve compliance, and streamline operations with IRB, IBC, consulting, and research technology solutions.

- **OnCore.**
  Manage finances, protocol lifestyle, and patient lifecycle with the industry-leading enterprise research management system.

- **eREG.**
  Enhance regulatory compliance, boost staff productivity, and gain efficiency with an eRegulatory system ideal for remote workflows and monitoring.

- **IRB.**
  Utilize the IRB trusted by more than 80% of AACI members, 75% of Operation Warp Speed vaccine trials, the single IRB for NCI Cancer Moonshot, and exemplary IBC activation for gene therapy studies.

- **Consulting.**
  Leverage our GxP, QA, regulatory, and HRP experts to ensure compliance across your studies, and speed up your study activation and operational workflows with coverage analysis, study design, budget negotiation, and more.

Join us for Leveraging Integrated Clinical Research Solutions to Streamline Your Trials

Tuesday, October 13 | 3:30pm Central
**Comprehensive Genomic Profiling**

**HOW DOES CARIS DEFINE COMPREHENSIVE?**

22,000 DNA Genes, 62,000 mRNA Transcripts, Plus Proteins… for every patient!

**Why?**

22,000 DNA Genes
62,000 mRNA Transcripts

200,000+ Matched Patient Records

AI (Artificial Intelligence)

Clinical Outcomes

Unique, novel signatures improve outcomes and overall survival for patients.
- Patients are our priority
- Patients of today helping patients of tomorrow
- Profile first

**Caris Life Sciences**

The Molecular Science Company. Independent and Unbiased.

Learn more at www.CarisLifeSciences.com/CGP

© 2020 Caris Life Sciences. All rights reserved. TN0584

**GO PAPERLESS. STAY COMPLIANT.**

Are you tired of fighting with messy binders, cluttered inboxes or misplaced documents?

Has the already heavy workload of tasks associated with the administration and management of regulatory and trial paperwork become even more compounded by COVID-19?

Do you want to reduce those tasks while improving your efficiency, compliance and transparency?

It's time to partner with Complion. Our cloud-based eReg solution enables you to:

- Quickly find the right document with better organized files, standard templates, and powerful keyword search.
- Reduce time managing PI delegation records, Safety Reports, CVs, Licenses and training with Part 11 compliant signatures and site-centric workflows.
- Eliminate printing and redundancy by connecting to existing email, CTMS, IRB or EMR systems without costly development or custom coding.
- Instantly collaborate across multiple sites and institutions.

Ready to learn more? Let's schedule a demo.
Contact us at 800-615-9077 or info@complion.com.

www.complion.com
You have patient safety, drug accountability, protocols, investigator satisfaction, team management, grants, NCI designations, training, and a million things to think about when managing research operations and accelerating cures. Your regulatory and source documentation shouldn’t be one of them.

Florence helps you, numerous AACI member institutes, and more than 8,000 study sites in 28 countries, optimize electronic document workflows and enable remote site access.

Learn more and see stories of other institutes using Florence to accelerate research. FlorenceStories.com

Prepare for the Future of Clinical Trials

Go paperless and enable remote monitoring today
Seamlessly exchange information with sponsors
Connect with patients virtually

Veeva SiteVault
Learn more at sites.veeva.com
2021 Meetings — Save the Date

July 13–15, 2021
Loews Chicago O'Hare Hotel

October 17 – 19, 2021
InterContinental Kansas City at the Plaza